annual operating profit:
-$479.00M-$128.94M(-36.83%)Summary
- As of today (September 18, 2025), RXRX annual operating income is -$479.00 million, with the most recent change of -$128.94 million (-36.83%) on December 31, 2024.
- During the last 3 years, RXRX annual operating profit has fallen by -$296.23 million (-162.07%).
- RXRX annual operating profit is now -667.13% below its all-time high of -$62.44 million, reached on December 31, 2019.
Performance
RXRX Operating profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly operating profit:
-$176.23M+$15.14M(+7.91%)Summary
- As of today (September 18, 2025), RXRX quarterly operating income is -$176.23 million, with the most recent change of +$15.14 million (+7.91%) on June 30, 2025.
- Over the past year, RXRX quarterly operating profit has dropped by -$75.68 million (-75.28%).
- RXRX quarterly operating profit is now -867.38% below its all-time high of -$18.22 million, reached on June 30, 2020.
Performance
RXRX quarterly operating profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM operating profit:
-$649.72M-$75.68M(-13.18%)Summary
- As of today (September 18, 2025), RXRX TTM operating income is -$649.72 million, with the most recent change of -$75.68 million (-13.18%) on June 30, 2025.
- Over the past year, RXRX TTM operating profit has dropped by -$254.35 million (-64.33%).
- RXRX TTM operating profit is now -3442.04% below its all-time high of -$18.34 million, reached on March 31, 2020.
Performance
RXRX TTM operating profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Operating profit Formula
Operating Profit = Gross Profit − Operating Expenses
RXRX Operating profit Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -36.8% | -75.3% | -64.3% |
| 3 y3 years | -162.1% | -166.2% | -178.2% |
| 5 y5 years | -667.1% | -867.4% | -1677.1% |
RXRX Operating profit Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -162.1% | at low | -189.0% | +7.9% | -178.2% | at low |
| 5 y | 5-year | -667.1% | at low | -867.4% | +7.9% | -1677.1% | at low |
| alltime | all time | -667.1% | at low | -867.4% | +7.9% | -3442.0% | at low |
RXRX Operating profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$176.23M(-7.9%) | -$649.72M(+13.2%) |
| Mar 2025 | - | -$191.37M(+4.1%) | -$574.03M(+19.8%) |
| Dec 2024 | -$479.00M(+36.8%) | -$183.77M(+86.8%) | -$479.00M(+21.5%) |
| Sep 2024 | - | -$98.35M(-2.2%) | -$394.17M(-0.3%) |
| Jun 2024 | - | -$100.54M(+4.4%) | -$395.36M(+5.0%) |
| Mar 2024 | - | -$96.34M(-2.6%) | -$376.54M(+7.6%) |
| Dec 2023 | -$350.06M(+42.5%) | -$98.93M(-0.6%) | -$350.06M(+12.2%) |
| Sep 2023 | - | -$99.55M(+21.8%) | -$312.11M(+13.4%) |
| Jun 2023 | - | -$81.72M(+17.0%) | -$275.13M(+6.0%) |
| Mar 2023 | - | -$69.86M(+14.6%) | -$259.61M(+5.7%) |
| Dec 2022 | -$245.73M | -$60.98M(-2.5%) | -$245.73M(-1.6%) |
| Sep 2022 | - | -$62.57M(-5.5%) | -$249.71M(+6.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$66.19M(+18.2%) | -$233.53M(+12.1%) |
| Mar 2022 | - | -$55.98M(-13.8%) | -$208.27M(+13.9%) |
| Dec 2021 | -$182.78M(+116.0%) | -$64.96M(+40.0%) | -$182.78M(+27.5%) |
| Sep 2021 | - | -$46.40M(+13.4%) | -$143.40M(+20.0%) |
| Jun 2021 | - | -$40.93M(+34.3%) | -$119.47M(+23.5%) |
| Mar 2021 | - | -$30.48M(+19.2%) | -$96.76M(+14.3%) |
| Dec 2020 | -$84.61M(+35.5%) | - | - |
| Dec 2020 | - | -$25.58M(+13.8%) | -$84.61M(+43.3%) |
| Sep 2020 | - | -$22.47M(+23.4%) | -$59.03M(+61.5%) |
| Jun 2020 | - | -$18.22M(-0.7%) | -$36.56M(+99.3%) |
| Mar 2020 | - | -$18.34M | -$18.34M |
| Dec 2019 | -$62.44M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual operating income?
- What is the all time high annual operating profit for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual operating profit year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly operating income?
- What is the all time high quarterly operating profit for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly operating profit year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM operating income?
- What is the all time high TTM operating profit for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM operating profit year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual operating income?
The current annual operating profit of RXRX is -$479.00M
What is the all time high annual operating profit for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual operating income is -$62.44M
What is Recursion Pharmaceuticals, Inc. annual operating profit year-on-year change?
Over the past year, RXRX annual operating income has changed by -$128.94M (-36.83%)
What is Recursion Pharmaceuticals, Inc. quarterly operating income?
The current quarterly operating profit of RXRX is -$176.23M
What is the all time high quarterly operating profit for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly operating income is -$18.22M
What is Recursion Pharmaceuticals, Inc. quarterly operating profit year-on-year change?
Over the past year, RXRX quarterly operating income has changed by -$75.68M (-75.28%)
What is Recursion Pharmaceuticals, Inc. TTM operating income?
The current TTM operating profit of RXRX is -$649.72M
What is the all time high TTM operating profit for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM operating income is -$18.34M
What is Recursion Pharmaceuticals, Inc. TTM operating profit year-on-year change?
Over the past year, RXRX TTM operating income has changed by -$254.35M (-64.33%)